Journal of Endocrinological Investigation最新文献

{"title":"Inhibition of endolysosomal two-pore channel 2 (TPC2) induces osteoblast differentiation and matrix mineralization while targeting autophagy.","authors":"Azadeh Montaseri, Michela Rossi, Giulia Battafarano, Anna Riccioli, Fioretta Palombi, Claudia Giampietri, Domenico Liguoro, Rita Mancini, Martina Meucci, Biagio Palmisano, Mara Riminucci, Marco Keller, Franz Bracher, Christian Grimm, Kaoru Umehara, Wanchai De-Eknamkul, Antonio Filippini, Andrea Del Fattore","doi":"10.1007/s40618-026-02898-0","DOIUrl":"10.1007/s40618-026-02898-0","url":null,"abstract":"<p><strong>Purpose: </strong>Endolysosomal two-pore channels (TPCs) are non-selective cation channels that control the release of Ca²⁺ and Na⁺ from the endolysosomal lumen. TPCs also reportedly play a role in autophagy. Interestingly, autophagy regulates bone cell differentiation and function. This study aimed to provide an in-depth insight into TPC2's action in the autophagy pathway to control osteoblast differentiation and function.</p><p><strong>Methods: </strong>Primary human mesenchymal stem cells (hMSCs) and human osteoblast-like cells (Saos-2) were used to assess osteoblastogenesis and bone mineralization, respectively. MSCs were treated with different pharmacological TPC2 inhibitors including naringenin, tetrandrine, MT-8 and SG-094 during their differentiation process. Finally, formation of osteoblasts and in vitro bone mineralization were evaluated by alkaline phosphatase, alizarin red S and Von Kossa staining. Western blot analysis was performed to investigate the expression of autophagy-related molecules.</p><p><strong>Results: </strong>The inhibition of TPC2 activity stimulates osteoblast differentiation from hMSCs and bone mineralization by Saos-2 cells. Interestingly, TPC2 inhibition reduces beclin-1 and LC3-II expression while that of the mammalian target of rapamycin (mTOR), the master regulator of autophagy, increases. Inhibition of mTOR activity by rapamycin reverses osteoblast differentiation induced by TPC2 inhibitor SG-094.</p><p><strong>Conclusion: </strong>Inhibition of TPC2 channel activity increases osteoblast differentiation and bone mineralization in vitro and interferes with the completion of autophagy, upregulating phosphorylated mTOR.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2421-2438"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential associations of traditional and shape-based adiposity indices with steatosis and fibrosis risk in metabolic dysfunction-associated steatotic liver disease.","authors":"Giulio Geraci, Valentina Paternò, Alessandro Vitello, Marcello Maida, Federico Bonomo, Samuele Sanfilippo, Simone Argento, Carlo Maida, Giuliano Cassataro, Roberto Baratta, Gabriele Costanzo, Francesco Pallotti, Calogero Geraci, Roberta Esposito, Riccardo Polosa, Pietro Ferrara","doi":"10.1007/s40618-026-02908-1","DOIUrl":"10.1007/s40618-026-02908-1","url":null,"abstract":"<p><strong>Background: </strong>Traditional anthropometric indices reflect total body adiposity, whereas novel shape-based indices capture fat distribution and unfavorable adiposity. How these measures relate to hepatic steatosis and fibrosis risk across the spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.</p><p><strong>Methods: </strong>In this cross-sectional study, 222 patients with MASLD were included. Body mass index (BMI), waist circumference (WC), a body shape index (ABSI) and body roundness index (BRI) were evaluated. Hepatic steatosis was assessed by ultrasonography using the Bright Liver Echo Pattern (BLEP), while fibrosis risk was estimated using the Fibrosis-4 (FIB-4) index.</p><p><strong>Results: </strong>BMI, WC, and BRI were higher in individuals with moderate-to-severe hepatic steatosis (BLEP ≥ 2), whereas ABSI did not differ according to steatosis severity. In multivariable logistic regression, BMI was independently associated with BLEP ≥ 2 (OR 1.19; 95% CI 1.05-1.35; p = 0.006), together with fasting glucose. ABSI showed a positive correlation with FIB-4 (r = 0.248; p < 0.001), whereas BMI did not. In multivariable linear regression, ABSI remained independently associated with FIB-4 (β = 0.145; p = 0.017), while BMI and BRI were not. Receiver operating characteristic analyses showed that BMI and WC best discriminated moderate-to-severe steatosis, whereas ABSI demonstrated the highest accuracy for identifying advanced fibrosis risk (FIB-4 ≥ 2.67; AUC 0.714; p = 0.004).</p><p><strong>Conclusions: </strong>Traditional and shape-based anthropometric indices capture complementary aspects of MASLD. Integrating measures of total adiposity and body shape may improve risk stratification in MASLD, although findings require confirmation using direct measures of liver fibrosis.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2485-2495"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP.","authors":"Didem Helvacioglu, Nilsu Turkmen, Serap Turan, Tulay Guran, Belma Haliloglu, Busra Gurpinar Tosun, Ahmet Kahveci, Abdullah Bereket","doi":"10.1007/s40618-026-02925-0","DOIUrl":"10.1007/s40618-026-02925-0","url":null,"abstract":"<p><strong>Purpose: </strong>Gonadotropin-releasing-hormone (GnRH) stimulation test is used for assessment of gonadotropic activation in patients with central precocious puberty (CPP). However, it is invasive and GnRH preparation is not available in all countries. Depot-leuprolide acetate (dLA), used for the treatment of CPP, stimulates gonadotropins briefly before suppressing them. This study aimed to evaluate the utility of luteinizing hormone (LH) level measured 40-minutes after dLA injection for assessing gonadotropic activation compared to GnRH stimulation test.</p><p><strong>Methods: </strong>In this prospective study, girls with idiopathic CPP were randomized to receive dLA 3.75 mg/4 weeks IM, 11.25 mg/12 weeks SC or 11.25 mg/12 weeks IM. A standard GnRH test was performed before (baseline) and after 6 months of treatment. Forty minutes after the first dLA injection, LH and follicle-stimulating hormone (FSH) levels were measured, and the same measurements were repeated after 6 months of treatment.</p><p><strong>Results: </strong>The study recruited 132 girls. Peak LH on the GnRH test did not differ from the 40-minute-post-dLA LH levels [11.0(6.8-17.1) vs. 9.4(5.8-16.6); p = 0.06]. There were no significant differences between the treatment groups. Using the GnRH test peak of LH ≥ 5 IU/L as the gold-standard, ROC analysis identified the optimal cut-off of post-dLA injection LH ≥ 5.4 IU/L on initial measurement (sensitivity = 86%, specificity = 90% and AUC = 0.91). At 6 months, peak LH levels in treatment groups were similarly suppressed (2.1 ± 1.6, 2.5 ± 1.8, 2.2 ± 0.9; p = 0.2011). Furthermore, post- dLA LH cut-off of < 3.07 IU/L yielded an AUC = 0.83, sensitivity = 80.8% and specificity = 75.5%.</p><p><strong>Conclusion: </strong>The 40-minute post-dLA LH provided clinically useful information concerning gonadotropic activity for both diagnosis and treatment monitoring and may provide a practical and clinically informative alternative in selected settings, particularly when standard GnRH testing is not readily available.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2375-2383"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148036663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mining safety signals of PD-1/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database.","authors":"Ruoxuan Pan, Tingting Chen, Guimu Guo, Sijie Chang, Jintuo Zhou, Peiguang Niu, Xiaoping Zeng, Jinhua Zhang","doi":"10.1007/s40618-026-02901-8","DOIUrl":"10.1007/s40618-026-02901-8","url":null,"abstract":"<p><p>PurposeThis study evaluated the potential association between programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors and adrenal insufficiency (AI) in the Food and Drug Administration Adverse Event Reporting System (FAERS) database to explore drug safety signals. MethodsThis study extracted real-world adverse event reports from the FAERS database spanning 2004 Q1 to 2024 Q4. Multiple disproportionality analysis methods were employed to evaluate the association between PD-1/PD-L1 inhibitors and AI, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) based on Information Component (IC), and Multi-item Gamma Poisson Shrinker (MGPS) methods. ResultsA total of 164,152 adverse events related to PD-1/PD-L1 inhibitors were identified in the FAERS database, among which 1,023 cases were associated with AI. The top three drugs with the highest signal strength, measured by IC₀₂₅, tislelizumab (IC₀₂₅ = 5.53), pembrolizumab (IC₀₂₅ = 4.01), and cemiplimab (IC₀₂₅ = 3.53). Time-to-onset analysis indicated that durvalumab and pembrolizumab were associated with the highest risk of AI during the initial treatment period (3-6 months), followed by a declining trend. Subgroup analysis showed a higher risk in patients over 65, males at significantly higher risk than females, and a stronger association of gastric cancer with AI risk signals than other cancers. Additionally, combination therapy with paclitaxel or lenvatinib mesylate was associated with an increased risk of AI onset.ConclusionsPD-1/PD-L1 inhibitors carry a potential risk of AI, and emphasis should be placed on early monitoring during clinical use to reduce the occurrence of adverse events.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2327-2338"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of patients with hypoparathyroidism: a Delphi consensus analysis.","authors":"Luisella Cianferotti, Giovanna Mantovani, Roberto Ravasio, Alessia Dinoia, Andrea Torriani, Fabio Vescini, Iacopo Chiodini","doi":"10.1007/s40618-026-02861-z","DOIUrl":"10.1007/s40618-026-02861-z","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic hypoparathyroidism is a rare endocrine disorder characterized by parathyroid hormone (PTH) deficiency and associated with substantial clinical and therapeutic challenges. Despite conventional therapy and the off-label use of teriparatide, important unmet needs persist regarding metabolic control, prevention of long-term complications, and health-related quality of life (HRQoL). Although recent international and national guidelines have updated recommendations on chronic hypoparathyroidism management, relevant uncertainties and heterogeneity remain in real-world practice, particularly concerning the identification of patients not adequately controlled with conventional therapy, the therapeutic positioning and timing of PTH replacement therapy, monitoring strategies, and the implementation of structured care pathways. This study aimed to assess the level of expert consensus on the current management of hypoparathyroidism in Italy and to identify key gaps and potential areas for therapeutic and organizational improvement.</p><p><strong>Methods: </strong>A consensus survey was conducted using the Delphi method in two rounds. The Steering Committee defined 41 statements on the management of hypoparathyroidism, which were submitted to 20 expert clinicians via an online survey. Consensus was considered to have been reached with ≥ 70% of responses 4-5 (Likert scale 1-5).</p><p><strong>Results: </strong>The completion rate was 100%. Consensus was reached for 39/41 statements (95.1%). Experts highlighted the limitations of conventional therapy and the off-label use of teriparatide, recognizing the impact of the disease on quality of life and the need for care pathways. The need for hormone replacement therapy was also emphasized, together with the importance of structured monitoring and multidisciplinary follow-up.</p><p><strong>Conclusion: </strong>Chronic hypoparathyroidism remains a clinically challenging condition with significant unmet needs. This Italian Delphi consensus complements recent international and national guidelines by providing expert-driven insights on real-world implementation, therapeutic positioning, monitoring, and care pathway development within the Italian healthcare context, supporting the need to introduce hormone replacement therapy and improve multidisciplinary management.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2097-2112"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid abnormalities in acromegaly in the era of improved disease control: a two-stage study.","authors":"Luciana P S Diniz Leite, Beatriz S Soares da Rocha, Gustavo A P Diniz Leite, Gabriel A P Diniz Leite, Juliana Beaudette Drumond, Lucas G de O Freitas, Izabella S Freitas, Ângela C Leal, Nathalie O Santana, Adriana M Lamego Rezende, Enaldo V Melo, Arthur M Pereira Oliveira, Elenilde G Santps, Viviane C Campos, Roberto Salvatori, Manuel H Aguiar-Oliveira","doi":"10.1007/s40618-026-02919-y","DOIUrl":"10.1007/s40618-026-02919-y","url":null,"abstract":"<p><strong>Purpose: </strong>Acromegaly is associated with increased risk of diffuse or nodular goiter and possibly of thyroid cancer. The aim of this study was to verify whether these findings persist in the current scenario of improved disease control.</p><p><strong>Methods: </strong>A two-steps protocol was carried out:. In the first (retrospective), clinical and laboratory data (including 969 IGF-I measurements), and the frequency of thyroid cancer were recorded for 92 acromegaly patients over a 28-year period. The annual control percentage was defined as the average of the ratios between each of the 969 IGF-I measurements over the total follow-up period and the respective upper age limit (IGF-I/ULN) less than 1.Acromegaly activity was determined at the last visit. In the second step (cross-sectional), 74 of the 92 acromegaly patients underwent thyroid ultrasound and were subjected to a two-stage cluster analysis, with the aim of grouping them into homogeneous clusters.</p><p><strong>Results: </strong>70% of the 92 patients had inactive disease, with a median control rate of 50%, with four cases of thyroid cancer (4.3%), only one in a patient with active disease. Two-thirds of the 74 patients (evaluated by ultrasound) had nodules, and 27% had diffuse thyroid hyperplasia. Three clusters were segregated with high significant differences in sex and echotextural alterations (p < 0.0001 in both cases). Age, number of nodules, thyroid volume and follow-up time were similar between the clusters.</p><p><strong>Conclusion: </strong>No inherent thyroid changes were apparently identified in a large cohort of acromegaly patients. Better control during follow-up may attenuate thyroid manifestations in acromegaly.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2245-2253"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism.","authors":"Baris Afsar, Rengin Elsurer Afsar, Geetha Maddukuri","doi":"10.1007/s40618-026-02909-0","DOIUrl":"10.1007/s40618-026-02909-0","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a chronic, multifactorial condition which is a global health challenge. In general, obesity is defined by excessive fat accumulation and associated with the risk of numerous conditions, including type 2 diabetes mellitus (T2DM), cardiovascular disease, heart failure, and metabolic dysfunction-associated steatotic liver disease, and some types of cancer contributing to increased morbidity and mortality. Mineralocorticoid receptor antagonists (MRAs) are used for a long time for management of cardiovascular disease and non-steroidal MRAs also showed kidney protection. Apart from these, there is growing literature showing that MRAs effecting fat mass and fat metabolism. In this review, we summarised the effects of MRAs on fat mass and fat metabolism.</p><p><strong>Results: </strong>In general, studies showed that MRAs reduced fat mass in various organs which is associated decreased oxidative stress, inflammation, and insulin resistance. Importantly, MRAs increased adipose tissue browning and decrease white adipose tissue mass. Up to now, the studies showed no safety signals and these favorable effects are independent of blood pressure reduction. Discussion A part from hemodynamic effects, MRAs have beneficial impacts on fat mass and fat metabolism. Currently, the underlying mechanisms for these effects are not clear Conclusions: Preliminary studies have shown that MRAs have favorable impact on fat metabolism and fat mass. Studies needed to highlight underlying mechanisms..</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2205-2218"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in primary aldosteronism, medical vs surgical treatment: a systematic review and meta-analysis.","authors":"Merel Wever, Christian Basile, Emanuele Bobbio, Eleftheria Gkaniatsa, Nienke Biermasz, Daniela Esposito, Oskar Ragnarsson","doi":"10.1007/s40618-026-02903-6","DOIUrl":"10.1007/s40618-026-02903-6","url":null,"abstract":"<p><strong>Introduction: </strong>Primary aldosteronism (PA) can be managed either by unilateral adrenalectomy (ADX) or pharmacologically with mineralocorticoid receptor antagonists (MRA). Several recent meta-analyses have examined how these treatment modalities affect cardiovascular outcomes in patients with PA. However, the impact of treatment on quality of life (QoL) remains largely unexplored.</p><p><strong>Objective: </strong>To synthesize data from previous studies that have investigated QoL in either medically or surgically treated patients with PA.</p><p><strong>Methods: </strong>A literature search was conducted in May 2025 in PubMed, Embase and Web of Science. Studies containing data on QoL before and after ADX or MRA were selected.</p><p><strong>Results: </strong>Fifteen studies evaluated QoL after treatment for PA. Most comparative studies reported greater and faster QoL improvement after ADX than with MRA. QoL consistently improved after ADX, whereas results with MRA were variable and less consistent. Patients treated with MRA were older than patients treated with ADX and frequently received low MRA doses. Five studies (259 ADX-treated and 88 MRA-treated patients) were included in a meta-analysis. Baseline QoL did not differ between treatment groups. At 6 months, QoL improved in both groups, with no statistically significant difference between ADX and MRA.</p><p><strong>Conclusion: </strong>Treatment of PA is associated with improved QoL following both ADX and MRA therapy. Although several studies suggest superior outcomes after adrenalectomy, the meta-analysis did not show a significant difference at 6 months of follow-up. The limited number of patients, short follow-up duration, and potential undertreatment with MRA represent important limitations.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2305-2313"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Goiter under the Mantle. Madonna of Mercy (1400) of Santa Maria in Selva in Locarno.","authors":"Michele Augusto Riva","doi":"10.1007/s40618-026-02841-3","DOIUrl":"10.1007/s40618-026-02841-3","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2577-2578"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of gut microbiota in thyroid cancer: from pathogenesis to diagnosis and treatment.","authors":"Lei-Jun He, Si-Cheng Zhang, Yong-Cong Cai","doi":"10.1007/s40618-026-02892-6","DOIUrl":"10.1007/s40618-026-02892-6","url":null,"abstract":"<p><p>In recent years, the key role of the gut microbiota (GM) in the diagnosis, prognosis, and treatment of thyroid cancer (TC) has become increasingly clear. This review examines the complex interactions between gut dysbiosis and the occurrence and development of TC; focuses on changes in specific microbiotas that are directly related to tumor stage, lymph node metastasis, and drug resistance; and evaluates the potential of these microbiotas as novel biomarkers for treating TC. To elucidate the underlying molecular mechanisms, this review systematically evaluates the pathways through which the GM regulates the host immune response through metabolites (such as short-chain fatty acids and lipopolysaccharides) and reveals the core role of chronic inflammation in the formation of the microenvironment and the immune escape of TC. Furthermore, by exploring the effects of the microbiota on the hypothalamic-pituitary-thyroid axis and the peripheral thyroid hormone conversion, this review elucidates the profound role of the GM in the regulation of thyroid homeostasis. Based on this evidence, this review highlights the clinical applications of intervention strategies targeting the microbiota, including probiotics, dietary adjustments, and fecal microbiota transplantation, as adjuvant approaches for TC management.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2191-2204"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}